Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Shin Maeda, Hisashi Hidaka et al.|Hepatology Research|2020Cited by 38
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinomaShigeo Shimose, Takumi Kawaguchi, Atsushi Hiraoka et al.|Hepatology Research|2022Cited by 31
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Margherita Rimini, Toshifumi Tada et al.|Liver International|2021Cited by 25